Amounts in thousands of United States dollars
September 30, September 30,
2024 2023
------------------------------------------- --------------- ---------------
Cash $ 103,710 $ 33,702
Prepaids and other assets 24,402 115,420
--------------- ---------------
Total assets $ 128,112 $ 149,122
Current liabilities 3,301 3,495
Long-term lease liability 205 -
Shareholders' deficiency 124,606 145,627
--------------- ---------------
Total liabilities and shareholders' equity $ 128,112 $ 149,122
=========================================== =============== ===============
ESSA PHARMA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Amounts in thousands of United States dollars, except share and per share data
Three months Three months
ended ended Year ended Year ended
September 30, September 30, September 30, September 30,
2024 2023 2024 2023
------------------ --------------------- ------------------- ------------------- -------------------
OPERATING EXPENSES
Research and
development $ 4,188 $ 5,226 $ 21,207 $ 21,323
Financing costs - 1 - 7
General and
administration 3,507 1,922 13,214 10,812
--------------------- ------------------- ------------------- -------------------
Total operating
expenses (7,695) (7,149) (34,421) (32,142)
--------------------- ------------------- ------------------- -------------------
Interest and
other items 1,339 1,668 5,878 5,560
--------------------- ------------------- ------------------- -------------------
Net loss before
taxes (6,356) (5,481) (28,543) (26,582)
Income tax expense
(recovery) -- -- - (2)
--------------------- ------------------- ------------------- -------------------
Net loss for the
period $ (6,356) $ (5,483) $ (28,543) $ (26,584)
OTHER
COMPREHENSIVE
LOSS
Unrealized gain
(loss) on short-
term investments 37 2 57 15
--------------------- ------------------- ------------------- -------------------
Loss and
comprehensive
loss for the
period $ (6,319) $ (5,479) $ (28,486) $ (26,569)
Basic and diluted
loss per common
share $ (0.14) $ (0.12) $ (0.64) $ (0.60)
================== ===================== =================== =================== ===================
Weighted average
number of common
shares
outstanding 44,366,126 44,092,374 44,277,050 44,089,557
================== ===================== =================== =================== ===================
View original content:https://www.prnewswire.com/news-releases/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-fourth-quarter-and-year-ended-september-30-2024-302333326.html
SOURCE ESSA Pharma Inc
(END) Dow Jones Newswires
December 17, 2024 07:00 ET (12:00 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。